S-1/A: ZyVersa Therapeutics Faces Nasdaq Delisting, Seeks Capital Amid Going Concern Doubts

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, is registering shares for resale to raise capital following its delisting from Nasdaq and amidst significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Summary

• ZyVersa Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs for chronic renal and inflammatory diseases.
• The company has two proprietary drug development platforms: Cholesterol Efflux Mediator VAR 200 for renal diseases (lead indication: FSGS, currently in Phase 2a for diabetic kidney disease) and Inflammasome ASC Inhibitor IC 100 for inflammatory conditions (lead indication: obesity with cardiometabolic complications, nearing IND submission in H2-2025).
• The company's common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025, due to noncompliance with minimum bid price requirements, and now trades on the Pink Limited Market.
• ZyVersa is registering up to 23,624,938 shares of common stock for resale by selling stockholders, including 17,500,008 shares related to an Equity Purchase Agreement (EPA) with Williamsburg Venture Holdings, LLC and 6,124,930 shares from Series A-4 Warrants issued to Armistice Capital, LLC.
• The company may receive up to $10 million in gross proceeds from the sale of shares under the EPA with Williamsburg and approximately $4.1 million if all Series A-4 Warrants are exercised for cash.
• As of June 30, 2025, the company had 7,935,921 shares of common stock outstanding; if all registered shares are issued, the total outstanding shares would be 31,560,859, indicating significant potential dilution.
• The independent registered public accounting firm's report for the year ended December 31, 2024, expresses substantial doubt about the company's ability to continue as a going concern, with current cash on hand sufficient only on a month-to-month basis.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the Nasdaq delisting, the 'going concern' warning from auditors, and the severe liquidity issues. While there are ongoing drug development programs and potential capital raises, these are overshadowed by the company's precarious financial state and market challenges.

Positives

• The company has two proprietary drug development platforms, VAR 200 and IC 100, with potential for multiple indications.
• VAR 200 has an Investigational New Drug (IND) application allowed by the FDA for a Phase 2a trial in FSGS, and a Phase 2a trial for diabetic kidney disease has been initiated to obtain quicker proof-of-concept data.
• IC 100's preclinical development is nearing completion, with a planned IND submission in H2-2025 and a Phase 1 trial initiation in healthy overweight patients.
• The company has secured an equity line of credit with Williamsburg Venture Holdings, LLC for up to $10 million, providing a potential source of capital.
• The company received approximately $2.05 million in gross proceeds from the exercise of Series A-2 and Series A-3 Warrants.

Negatives

• Trading in the company's common stock on The Nasdaq Capital Market was suspended on July 17, 2025, due to noncompliance with minimum bid price requirements, resulting in a delisting.
• The company's independent registered public accounting firm's report for the year ended December 31, 2024, contains an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern.
• Current cash on hand is only sufficient to meet anticipated cash requirements on a month-to-month basis.
• The company has not generated any revenue from operations since inception and has incurred substantial net losses to date.
• The issuance of up to 23,624,938 shares for resale by selling stockholders may cause substantial dilution to existing stockholders.
• The common stock now trades on the Pink Limited Market, which is less regulated and may lead to unfavorable impacts on stock price and liquidity, including potential abuses, volatility, and shorting.

Risks

• Investors may lose all of their investment due to the high degree of risk associated with the securities.
• The actual number of shares sold under the Equity Purchase Agreement (EPA) or issued upon exercise of Series A-4 Warrants, and thus the actual gross proceeds, are uncertain and may be less than anticipated.
• The Series A-4 Warrants may not be exercised if their exercise price is higher than the prevailing market price of the common stock, limiting potential proceeds.
• Restrictions in the EPA, such as the 19.99% beneficial ownership limitation and the Exchange Cap, may limit the company's ability to utilize the full $10 million facility.
• Investors purchasing shares at different times may pay different prices and experience varying levels of dilution.
• The trading of common stock on the Pink Limited Market may result in unfavorable impacts on stock price and liquidity, and may make it more difficult for broker-dealers to recommend the stock.
• The company may be unable to continue as a going concern, potentially leading to liquidation of assets at significantly lower values.
• Substantial additional capital is needed to develop and commercialize product candidates, and there are no commitments for additional financing.
• Failure to raise sufficient capital could force delays, reductions, or elimination of product development programs.
• Future equity raises could significantly dilute existing stockholders' ownership.
• Raising capital through indebtedness may lead to restrictive covenants and divert funds from research and development.
• Collaborations and licensing arrangements may require relinquishing rights to technologies or product candidates on unfavorable terms.
• Reliance on third parties for technology, intellectual property, and operations poses risks.
• General economic and financial market conditions, including supply chain disruptions and inflationary cost pressures, could negatively impact the business.
• The possibility of an economic recession and geopolitical changes pose risks.
• The outbreak of infectious diseases could disrupt business plans, product development, and clinical trials.
• Litigation and regulatory enforcement risks could divert management time and attention and incur additional costs.

Future Outlook

The company plans to use any proceeds from the capital raises for working capital and general corporate purposes. It expects research and development expenses to increase as it progresses clinical trials for VAR 200 and continues preclinical development of IC 100. The company aims to advance IC 100 toward a planned IND submission in H2-2025, followed by initiation of a Phase 1 trial. It is also seeking to uplist to the OTCQB Venture Market, though there is no assurance of success.

Management Comments

• Our mission is to develop drugs that optimize health outcomes and improve patients quality of life.
• Our strategy is to focus on indication expansion to maximize commercial potential.
• Our management will have broad discretion in the application of the net proceeds from the offering.

Industry Context

ZyVersa Therapeutics operates in the highly competitive and regulated biopharmaceutical industry, specifically focusing on rare renal and inflammatory diseases. As a clinical-stage company, it faces significant R&D costs and the inherent uncertainties of drug development, including regulatory approvals and clinical trial success. The delisting from Nasdaq to the Pink Limited Market is a significant setback, typically associated with smaller, higher-risk companies struggling to meet exchange listing standards, which can severely impact investor confidence and access to capital compared to peers listed on major exchanges.

Comparison to Industry Standards

• The delisting from Nasdaq to the Pink Limited Market is a significant negative deviation from industry standards for publicly traded biopharmaceutical companies, which typically seek to maintain listing on major exchanges like Nasdaq for liquidity, visibility, and investor confidence.
• The 'going concern' explanatory paragraph in the independent auditor's report is a critical red flag, indicating severe financial distress and a high risk of business failure, which is not typical for stable, well-funded biopharmaceutical companies, even those in clinical stages.
• The reliance on an equity line of credit and warrant exercises for capital, coupled with the substantial potential dilution (from 7.9 million to 31.5 million shares), suggests a challenging funding environment compared to more established or successful clinical-stage companies that might secure less dilutive financing or larger, more stable partnerships.
• While clinical-stage companies often incur losses, the explicit statement of cash being sufficient only 'on a month-to-month basis' is indicative of a much more precarious financial position than many industry peers at similar development stages, who typically have longer cash runways.

Corporate Governance

Legal Proceedings

• The company faces general litigation and regulatory enforcement risks, which could divert management time and attention and incur additional costs.

Related Party Transactions

• The filing details the Equity Purchase Agreement with Williamsburg Venture Holdings, LLC and the Inducement Letter with Armistice Capital, LLC, which are significant financial transactions with selling stockholders.

Stakeholder Impact

• Shareholders face significant dilution of their ownership interests due to the potential issuance of up to 23,624,938 new shares.
• Shareholders may experience a decline in the value of their shares due to the Nasdaq delisting and the stock now trading on the less liquid Pink Limited Market.
• Shareholders face a high risk of losing all or part of their investment due to the company's 'going concern' doubt and need for substantial additional capital.
• The company's ability to continue operations and fund its drug development programs is directly impacted by its ability to raise additional capital, which affects its long-term viability for all stakeholders.

Next Steps

• The company will continue to progress clinical trials for VAR 200, including a larger Phase 2a/b protocol in patients with FSGS.
• The company plans to submit an IND for IC 100 in H2-2025, followed by initiation of a Phase 1 trial.
• The company may sell additional shares to Williamsburg Venture Holdings, LLC under the Equity Purchase Agreement to raise capital.
• The Selling Stockholder may exercise the Series A-4 Warrants, subject to stockholder approval for issuance of Warrant Shares.
• The company has 15 days from July 15, 2025, to request that the Nasdaq Council review the Panel's delisting decision.
• The company is currently seeking to uplist to the OTCQB Venture Market.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Clinical Stage, SEC Filing, S-1/A, Nasdaq Delisting, Going Concern, Equity Purchase Agreement, Warrants, Dilution, VAR 200, IC 100, Renal Disease, Inflammatory Disease, FSGS, Diabetic Kidney Disease, Obesity, Cardiometabolic Complications, OTC Markets, Pink Limited Market, Capital Raise, Drug Development